This is a prescription medicine. A prescription is required from your veterinarian before we can supply this product. Please ensure that you have read the "How to Order" page before ordering this item.
We apologise that we are unable to display a photograph of the packaging or provide you with more information regarding this prescription medicine. Australian legislation prohibits the advertisement of prescription drugs to consumers.
All of our products are APVMA or TGA approved and identical to those used by your veterinarian. Please call or email us if you have any queries about any of the products on our site.
|Drug Name and Strength||Sodium pentosan polysulfate 100mg/mL, |
Acetyl glucosamine 160mg/mL
|Indication||Aid in the treatment of noninfectious joint diseases in dogs, including osteoarthritis, especially in conditions affecting multiple joints; osteochondrosis dissecans; traumatic joint and periarticular inflammation in dogs.|
|Contraindications||Administration to animals with clotting defects, traumatic haemorrhage, infection, renal or hepatic failure; administration within two days of surgery.|
|Actions||N-Acetylglucosamine (NAG) is a monosaccharide derivative of glucose and is a principal component of glycosaminoglycans. In an experimental model of osteoarthritis in rabbits, intramuscular NAG resulted in reduced synovitis and chondrocyte damage compared with placebo and hyaluronan treatment. Injectable glucosamine is approved for use in horses to improve joint function.Laboratory studies conducted on chondrocytes have shown that pentosan polysulfate, as well as the combination of pentosan polysulfate and glucosamine, reduce gene expression of cyclooxygenase-II (COX 2) and production of prostaglandin E2 (PGE2) and nitric oxide. COX 2, PGE2 and nitric oxide are anti-inflammatory mediators. The combination of pentosan polysulfate and glucosamine showed greater reduction of these activities than pentosan alone.Pharmacology Pentosan polysulfate (PPS) is a semisynthetic polysaccharide polymer which possesses anti-inflammatory, antiarthritic and chondroprotective properties. These beneficial effects arise from direct anti-inflammatory activity; inhibition of neutrophil migration into joints; stimulation of hyaluronic acid synthesis by synovial fibroblasts which results in a marked increase in synovial fluid volume and viscosity; stimulation of chondrocytes and the biosynthesis of proteoglycans; and strong fibrinolytic activity which improves the circulation in subchondral bone and periarticular structures.|
|Precautions||If using after surgery or trauma, ensure that all haemorrhage has ceased.|
|Dosage and Administration||Give by subcutaneous or intramuscular injection. Give 0.3 mL/10 kg (PPS 3 mg/kg, NAG 4.8 mg/kg) on four occasions with an interval of five to seven days between injections. After withdrawal of the first dose, use remaining product within three months of opening.|
|Storage||Store below 25°C (air conditioning). Protect from light.|
|MSDS (external link)||Synovan 20ml MSDS|
|Label (external link)||Synovan 20ml Label|
|Manufacturer||Ceva Animal Health Pty Limited|